Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Considerable Resolve Needed for Proposed 80% Generic Target: JGA
May 25, 2015
- JSGM President Muto Calls for “Favorable Environment” to Promote Use of Biosimilars
May 25, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
- Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
- Generic Drug Use May Reach 60% Target Ahead of Schedule, but Raising Target to 80% Would Be “Difficult”: Director Jo of EAD
May 18, 2015
- PAFSC Second Committee to Review Safety Information of Takeda’s Hib Vaccine on May 28
May 18, 2015
- MHLW Announces 196 Newly Designated Intractable Diseases
May 15, 2015
- PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
- Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
- Chuikyo Approves Listing of 5 Drugs with Expected Peak Sales of Over 10 Billion Yen
May 14, 2015
- Sovaldi’s 5 Million Yen Price Tag OK’d for 12-Week Regimen, Listing on May 20
May 13, 2015
- MHLW Mulls Legal Disclosure of Drug Makers’ Clinical Research Payments
May 13, 2015
- Chuikyo to Begin Open Debates on Cost-Effectiveness Case Study from Late May: Official
May 12, 2015
- Govt to Hear Opinions from Trade, Professional Groups on Generic Promotion
May 12, 2015
- Applications for Sakigake Review System May Be Accepted from Early Stage of Development: Official
May 12, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 20 - May 10
May 11, 2015
- PMDA Evaluating Xalkori for Risk of Cardiac Failure
May 11, 2015
- Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
- 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
- DPC Hospitals with Generic Use Rates Above 60% More Than Doubled
May 1, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…